Suppression of thymosin β10 increases cell migration and metastasis of cholangiocarcinoma by Sirinapa Sribenja et al.
Sribenja et al. BMC Cancer 2013, 13:430
http://www.biomedcentral.com/1471-2407/13/430RESEARCH ARTICLE Open AccessSuppression of thymosin β10 increases cell
migration and metastasis of cholangiocarcinoma
Sirinapa Sribenja1,2, Kanlayanee Sawanyawisuth1, Ratthaphol Kraiklang1, Chaisiri Wongkham1,
Kulthida Vaeteewoottacharn1, Sumalee Obchoei1, Qizhi Yao2, Sopit Wongkham1 and Changyi Chen2*Abstract
Background: Thymosin β10 (Tβ10) expression is associated with malignant phenotypes in many cancers. However,
the role and mechanisms of Tβ10 in liver fluke-associated cholangiocarcinoma (CCA) are not fully understood. In
this study, we investigated the expression of Tβ10 in CCA tumor tissues and cell lines as well as molecular
mechanisms of Tβ10 in tumor metastasis of CCA cell lines.
Methods: Tβ10 expression was determined by real time RT-PCR or immunocytochemistry. Tβ10 silence or
overexpression in CCA cells was achieved using gene delivery techniques. Cell migration was assessed using
modified Boyden chamber and wound healing assay. The effect of silencing Tβ10 on CCA tumor metastasis was
determined in nude mice. Phosphorylation of ERK1/2 and the expression of EGR1, Snail and matrix
metalloproteinases (MMPs) were studied.
Results: Ten pairs of CCA tissues (primary and metastatic tumors) and 5 CCA cell lines were studied. With real time
RT-PCR and immunostaining analysis, Tβ10 was highly expressed in primary tumors of CCA; while it was relatively
low in the metastatic tumors. Five CCA cell lines showed differential expression levels of Tβ10. Silence of Tβ10
significantly increased cell migration, invasion and wound healing of CCA cells in vitro; reversely, overexpression of
Tβ10 reduced cell migration compared with control cells (P<0.05). In addition, silence of Tβ10 in CCA cells
increased liver metastasis in a nude mouse model of CCA implantation into the spleen. Furthermore, silence of
Tβ10 activated ERK1/2 and increased the expression of Snail and MMPs in CCA cell lines. Ras-GTPase inhibitor, FPT
inhibitor III, effectively blocked Tβ10 silence-associated ERK1/2 activation, Snail expression and cell migration.
Conclusions: Low expression of Tβ10 is associated with metastatic phenotype of CCA in vitro and in vivo, which
may be mediated by the activation of Ras, ERK1/2 and upregulation of Snail and MMPs. This study suggests a new
molecular pathway of CCA pathogenesis and a novel strategy to treat or prevent CCA metastasis.
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Cholangiocarcinoma (CCA), the malignancy of bile duct
epithelial cells, is a major cancer and a main health prob-
lem in the northeast of Thailand [1,2]. A global increase in
CCA related mortality and incidence of CCA have been
reported [3,4]. Several conditions associated with chronic
inflammation have been identified as risk factors for CCA.
Infection with the liver fluke (Opisthorchis viverrini) is the* Correspondence: jchen@bcm.tmc.edu
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reproduction in any medium, provided the ormajor risk factor of CCA in Thailand and Southeast Asia
[5]; whereas primary sclerosing cholangitis is the main risk
factor in Western countries [6].
Since CCA is difficult to diagnose at an early stage, al-
most all patients with CCA present with advanced, in-
curable disease. Even in patients who have undergone
complete surgical resection, the recurrence rate remains
quite high and the 5-year survival rate is unfavorable
[7,8]. CCA is a slow growing but highly metastatic can-
cer, which is the major cause of death in CCA patients.
Currently, there are no effective chemotherapeutic drugs
and sensitive tumor markers to diagnose or monitor the
tumor progression; most of CCA patients presentl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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blood vessels. Therefore, understanding the molecular
mechanism underlying CCA metastasis will lead to devel-
opment of new strategies for the diagnosis and the treat-
ment of CCA.
We have established the serial analysis of gene expres-
sions (SAGE) database of the primary and corresponding
metastatic tumors from a Thai male patient with CCA, as
well as high and low invasive CCA cell lines (http://cgap.
nci.nih.gov/SAGE). The differential expression of genes in
primary vs. metastatic tumors has been recently reported
[9]. Thymosin β10 (Tβ10) (TMSB10; SAGE tag: GGGG
AAATCG) was highly expressed in primary CCA tumors;
while it was reduced dramatically in the metastatic tumors
(6.5 fold decrease). Furthermore, immunohistochemical
(IHC) staining showed that the intensity of Tβ10 staining
in the primary CCA tumor tissue was higher than that in
the normal liver tissue. However, the impact of the sup-
pression of Tβ10 on the metastasis of CCA is not known.
Tβ10 is a member of the β-thymosin family, which is
widely distributed in many tissues with proven biological
activities as an actin sequestering protein involved in cell
motility. There are at least 15 β-thymosins discovered, of
which Tβ4 and Tβ10 are the most commonly found in
mammalian cells with Tβ4 being the major form (70 -
80%). Tβ4 and Tβ10 are mainly localized in cytoplasm,
and have high affinity to G-actin (actin monomer); while
the expression and functions of Tβ4 and Tβ10 are quite
different [10-13]. Tβ10 is differentially expressed in em-
bryogenesis and neuronal development. Its expression is
also increased in many inflammatory conditions and
tumorigenesis including cell proliferation, anti-apoptosis
and angiogenesis [14-16]. However, the functional asso-
ciation of Tβ10 with tumor metastasis is controversial.
High levels of Tβ10 expression were found in the meta-
static tumor of thyroid [17,18] and cutaneous malignancy
[19]; while the low level of Tβ10 expression was associated
with metastatic cervical carcinoma [20] and CCA [9].
In this study, the expression of Tβ10 in the primary
and metastatic CCA was determined. The functional
role of Tβ10 in CCA cell migration and metastasis was
studied in CCA cell lines and a nude mouse model of
CCA xenograft. Moreover, the possible signaling path-
way of Tβ10 in tumor metastasis was explored.
Methods
Patient tissues
Primary and corresponding metastatic CCA tissues (n =
10) were obtained from the specimen bank of the Liver
Fluke and Cholangiocarcinoma Research Center. Speci-
mens were collected from intrahepatic CCA patients
who underwent surgery at Srinagarind hospital, Faculty
of Medicine, Khon Kaen University. Informed consent
was obtained from each subject before surgery, and theHuman Research Ethics Committee at the Khon Kaen
University, Thailand approved the research protocol. The
specimens were kept frozen in Trizol (Invitrogen, CA) at -
80°C until use.
Cell lines and cell culture
CCA cell lines, KKU-M055, KKU-100, KKU-M156, KKU-
M213 and KKU-M214, were established from primary tu-
mors of Thai patients with different histological types
[21,22]. All cell lines were cultured in the DMEM medium
supplemented with 10% w/v fetal bovine serum (FBS), 100
U/mL penicillin and 100 μg/mL streptomycin at 37°C and
5% CO2.
Chemicals and reagents
DMEM medium, fetal bovine serum (FBS), trypsin EDTA,
Opti-MEM I medium and LipofectAmine™ 2000 transfec-
tion reagent were purchased from Invitrogen Life Technol-
ogy (Grand Island, NY). Puromycin and mouse anti-β-actin
antibody were purchased from Sigma Chemical Co (St
Louis, MO). Rabbit anti-Tβ10 antibody was purchased from
Biodesign International (Cincinnati, OH). Goat anti-rabbit
IgG (H&L) antibody conjugated to horseradish peroxidase
(HRP), goat anti-mouse IgG (H&L) antibody conjugated
to HRP and rabbit anti-SNAl1 were obtained from Cell
Signaling Technology Laboratories, Inc (Danvers, MA).
Rabbit anti-ERK1/2 antibody, mouse anti-pERK1/2 anti-
body, mouse anti-Histone H1 and rabbit anti-EGR1 anti-
bodies were obtained from Santa Cruz Biotechnology
(Dallas, TX). The chemiluminescence (ECL) Prime Western
Blotting Detection Reagent kit was purchased from GE
Healthcare (Piscataway, NJ). The Ambion RNAqueous-
4PCR kit and DNA removing kits were purchased from
Ambion (Austin, TX). The iQ SYBR Green supermix and
iScript cDNA synthesis kits were purchased from Bio-Rad
(Hercules, CA). All other chemicals were from Sigma.
RNA extraction
Total RNA was extracted using Ambion RNAqueous-
4PCR kit following the manufacture’s instruction. Briefly,
cells were lysed using lysis buffer, transferred to a mini-
column and centrifuged at 10,000 × g for 1 min. The col-
umn was washed and eluted in 60 μL of elution buffer.
RNA solution was treated with DNAse I to remove any
trace amounts of genomic DNA contamination. The frozen
mouse tumor tissues were soaked overnight in RNAlater-
ICE buffer (Ambion) before RNA extraction.
Real time RT-PCR
Tβ10 mRNA levels were determined using real time RT-
PCR. Briefly, mRNA was reverse-transcribed into cDNA
using the iScript cDNA synthesis kit and real time RT-
PCR was performed using the iQ SYBR Green supermix
kit (Bio-Rad, Hercules, CA). The PCR reaction of 100 nM
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Green supermix, ran for 40 cycles of 95°C for 20 sec and
60°C for 1 min. Each cDNA sample was run in duplicate.
β-actin was used as an internal loading control. The
mRNA levels of early growth response protein 1 (EGR1),
Snail, MMP3, MMP7 and MMP9 were similarly deter-
mined. The relative mRNA level was presented as unit
values of 2[Ct(β-actin)–Ct(Tβ10)]. The primers for human Tβ10
and β-actin were used as described in our previous publi-
cation [23].
Immunocytochemistry
Cells were seeded into a 24-well plate (2x104 cells/well)
and incubated in 5% CO2 at 37°C for 24 h. Cells were
fixed with 95% ethanol and washed twice in PBS, then
exposed to 0.3% hydrogen peroxide in absolute metha-
nol to quench endogenous peroxidase, and blocked with
5% FBS in PBS for 1 h. Cells were incubated with 1:500
rabbit anti-Tβ10 antibody (Biodesign, Cincinnati, OH) at
4°C overnight. To visualize antibody binding, cells were
reacted with anti-rabbit IgG EnVision (Dako, Carpinteria,
CA) for 30 min and diaminobenzidine (DAB) for 5 min.
The reaction was stopped by washing with distilled water
followed by Mayer’s haematoxylin staining.
Nuclear extraction
Cells were collected and washed with PBS. Cells were
lyzed in 1 mL hypotonic buffer (10 mM HEPES-KOH
pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.1% NP-40, 0.5
mM DTT and 1× Protease inhibitor cocktail) and incu-
bated on ice for 15 min. Nuclei fraction was collected by
centrifugation at 14,000 rpm for 30 sec, lyzed with 80 μL
of nuclear lysis buffer (50 mM HEPES-KOH pH 7.9,
10% glycerol, 420 mM KCl, 5 mM MgCl2, 0.1 mM DTT
and 1× Protease inhibitor cocktail), and incubated on ice
for 30 min. Nuclear extracts were obtained by centrifu-
gation at 14,000 rpm for 10 min.
Western blot
Cells were lysed with radioimmuno-precipitation assay
buffer (Pierce Biotechnology) for 30 min on ice. Whole cell
lysates were then collected after centrifugation at 12,000
rpm for 10 min at 4°C. Whole cell and nuclear fraction lys-
ate (30 μg) were loaded for ERK1/2, phosphorylated ERK1/
2, EGR1 and Snail detection, respectively. Protein bands
were separated with 12% Tris-Glycine SDS polyacrylamide
gel electrophoresis and then transblotted for 2 h at 4°C onto
Hybond-P PVDF membrane (GE Healthcare, Piscataway,
NJ). The membrane was probed with rabbit anti-ERK1/2
antibody (1:2,000), mouse anti-pERK antibody (1:1,000) and
anti-β-actin antibody (1:10,000) at room temperature for 1
h or rabbit anti-EGR1 (1:1000), rabbit anti-Snail (1:1000)
and mouse anti-Histone H1(1:1000) antibody at 4°C over-
night. Then, the membrane was incubated in a HRP-linkedsecondary antibody (1:20,000) for 1 h at room tempera-
ture; the immunoreactive bands were visualized using the
chemiluminescence Prime Western Blotting Detection Re-
agent kit.
Transient silence of Tβ10 by siRNA
KKU-M214 and KKU-100 CCA cells (with a high en-
dogenous Tβ10 expression; 2x104 cells/well) were seeded
into a 6-well plate for 24 h before transfection. The siRNA
specific sequence for targeting human Tβ10 (5′-GCGGA
GUGAAAUUUCCUAA-3′), corresponding to nucleotides
199 to 217 in the human sequence, was obtained from
Ambion (Austin, TX). The cells were transfected either
with 50 pM siTβ10 or a control scramble RNA. Transfec-
tions were carried out by using the LipofectAmine™ 2000
(Invitrogen, CA) according to the manufacturer’s instruc-
tions. After siRNA transfection, the plates were incubated
at 37°C for 24 h for further analysis and total RNA was
isolated with Trizol (Invitrogen, CA) reagent and reverse
transcription-PCR was done.
Establishment of stable cell lines and single
clone selection
To establish stable silence cell lines, shRNA plasmids and
full-length cDNA plasmids used in the present study were
purchased from OriGene and GeneCopoeia, respectively.
Stable cells expressing Tβ10 shRNA were created in KKU-
M055 and KKU-M214 cells by stably transfecting with
HuSH 29mer shRNA construct against Tβ10 (sh-Tβ10)
to elicit silencing by use of a retroviral delivery system
(OriGene Rockville, MD), following manufacturer’s in-
structions. These were compared to cell lines transfected
with the shRNA pRS non-effective GFP plasmids (sh-vec-
tor) as a negative control. The sequence of the Tβ10 shRNA
used in this study is as follows: 5′-AGATGGACACGA
GCCACAAGCTGCACTGT-3′. Briefly, Phoenix™ Ampho
Cells (Origene, Rockville, MD) were transfected with either
Tβ10 shRNA plasmid or shRNA vector control plasmid.
Viral supernatants were collected and transduced into
the parental KKU-M055 and KKU-M214 cells. Stable
cell lines expressing Tβ10 shRNA (M055-sh-Tβ10 and
M214-sh-Tβ10) or negative control vector (M055-sh-vector
and M214-sh-vector) were selected with the addition of
1 μg/mL puromycin into the medium.
To generate stable overexpression stable cell lines by
the lentiviral delivery system, full-length Tβ10 cDNA
plasmid called pReceiver-Tβ10-Lv105 overexpression con-
struct (GeneCopoeia) or pReceiver-eGFP-Lv105 vector as a
control was co-transfected into 293T cells with HIV pack-
ing plasmids (GeneCopoeia). Viral supernatants were col-
lected, filtered and transduced to the target cells. Stable cell
lines expressing Tβ10 (M055-Lenti-Tβ10 and M213-Lenti-
Tβ10) or GFP control (M055-Lenti-GFP and M213-Lenti-
GFP) were selected with adding 0.5 μg/mL of puromycin
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least 2 weeks before use in experiments. Tβ10 expression
was confirmed by real time RT-PCR analysis. Fluorescence
images of cells were captured to observe GFP signal in GFP
control cells.
For isolation of individual clones, the cells were grown
in the complete culture medium and then digested into
individual cells with 0.05% trypsin-EDTA and plated at a
density of 500 cells per 100-mm cell culture dish in the
presence of 0.5 μg/mL puromycin. Growth of the cell col-
onies was monitored by light microscopy. When the indi-
vidual colonies reached approximately 100 - 200 cells,
positions of the solitary colony were marked and single
cell clones were isolated by sterile cloning cylinders. Se-
lected 5-8 single cell clones were subjected to expansion
culture until sufficient amounts of cells were obtained.
In vitro migration
Cell migration was determined using a modified Boyden
chamber assay. Uncoated- and pre-coated Matrigel-inserts
(8 μm pore size Transwell®, Corning Inc., NY) were used
for migration and invasion assay, respectively. Cells (1×105)
were seeded into the upper compartment of the chamber
and 600 μL DMEM supplemented with 10% w/v FBS were
placed into the lower chamber. After incubation at 37°C for
an appropriate time, cells in the upper chamber were fixed
with 4% w/v paraformaldehyde for 15 min and stained with
0.5% w/v crystal violet in 25% v/v methanol. Cells in the
upper surface of the filter were scraped off using a cotton
swab and the number of migrated cells in the lower surface
was counted under microscope. Mean values of nine low-
power fields (100× magnification) were determined. For
stable cell lines, after cells migrated at 37°C for the specified
time, the cells were incubated with Calcein-AM (Molecular
Probes, Eugene, OR) for 1 h at 37°C before fixation. The
fluorescence was read from the bottom at an excitation
wavelength of 495 nm and emission wavelength of 520 nm.
Cells in the upper chamber were then removed, and cells
that had migrated onto the lower surface of the membrane
were quantified. The migration rate was presented as the
ratio of the mean fluorescence reading after scraping of the
cells divided by the reading before removal of the top cells.
Assays were done in triplicate and two independent experi-
ments were repeated. In stable cell lines which incubated
for migration more than 24 h, cells were pretreated with
12.5 ng/mL Mitomycin C (Sigma-Aldrich, St. Louis, MO)
for 3 h before seeded on the upper chamber to inhibit cell
proliferation.
Monolayer cell wound healing
The stable cells were seeded into 6-well plates (1.5x106
cells/well) and incubated in a humidified atmosphere of
5% CO2 at 37°C for 24 h. To inhibit cell proliferation,
a potential confounding variable, all wound assay cellswere pretreated with 5 μg/mL Mitomycin C for 3 h be-
fore the scrape line was made. Wounds were generated
on the surface of confluent monolayers using a sterile
pipette tip, followed by incubation with DMEM medium
supplemented with 10% FBS. Healing was observed at
different time points along the scrape line and a represen-
tative field for each cell line was photographed. Assays
were done in triplicate and two independent experiments
were repeated.
Nude mouse model
The following animal work was approved by the Office
for Protection from Research Risks and Animal Welfare
Act guidelines under an animal protocol approved by the
Baylor College of Medicine Institutional Animal Care and
Use Committee. Subconfluent and stable M214-sh-Vector-
GFP and M214-sh-Tβ10-GFP cells were harvested and
resuspended in serum-free DMEM. For intrasplenic injec-
tion, mice were anesthetized with 2.5% avertin, and a 0.5-
to 1-cm incision was made in the left subcostal region. The
spleen was exteriorized and the tumor cells (2 × 106 cells)
in a volume of 50 μL were injected into the tail of spleen of
5 to 6-week-old male nude mice (NCI Charles River); four
animals per group were used. The peritoneum and skin
were closed with a 4.0 surgical suture. Mouse body weight
was measured weekly. After 20 days of tumor implantation,
all mice were euthanized by an overdose of 2.5% avertin
and evaluated macroscopically for the presence of primary
tumors in the spleen and the metastases in the liver, lung
and abdominal cavity. To observe the gross nodule of liver
metastasis, the whole livers were imaged under a fiber
optic illumination LT-9900 Illumatool Bright Light System
(Lightools Research, Encinitas, CA), and imaging was car-
ried out at 470 nm with LT-9470FX 470 nm in Lightools
Filter Cup (Lightools Research, Encinitas, CA). The total
number of green fluorescent protein (GFP)-positive nod-
ules in the surface of all lobes of liver was quantified. Next,
the primary tumor site (spleen) and other organs (liver and
lungs) were harvested; the whole organ of each specimen
was embedded in Tissue-Tek® OCT compound (Sakura
Finetek Inc., Torrance, CA) and snap-frozen in liquid ni-
trogen before storage in -80°C for further histological stud-
ies. For the micrometastasis study, liver dissections were
sampled from the caudate and left lobe of each mouse. 14-
μm frozen sections were cut in a cryostat by following
cryostat manufacturer’s recommendation; then, the slides
were fixed in 4% paraformaldehyde for 10 min at room
temperature. All were visualized under an inverted fluores-
cent microscope using a 10× objective to verify the green
signal of GFP. Six fields of GFP indicated areas of each liver
section were taken and the number of micrometastasis was
quantified. Tumors inside the abdominal cavity were stored
in RNAlater solution (Ambion, Austin, TX) for real time
RT-PCR analysis.
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Experimental data were analyzed using SPSS 13.0 Win-
dows Evaluation software (SPSS Inc., Chicago, IL). All
quantitative data were expressed as mean or percentage ±
SD. Two-tailed Student’s t-test was used for comparison
between two groups. Statistical significance was established
at P < 0.05.Results
Tβ10 expression is decreased in the metastatic tumor of
liver fluke-induced cholangiocarcinoma
Our SAGE data indicates that Tβ10 may play a role in
CCA metastasis [9]. In this study, we determined the ex-
pression of Tβ10 in 10 pairs of CCA surgical specimens
(primary and metastatic tumor) and 5 CCA cell lines
previously isolated from the CCA tissues [21,22]. High
expression of Tβ10 was found in the primary CCA tumor;
while significantly low expression of Tβ10 was observed
in the metastatic tumor by real time RT-PCR analysis and
immunohistochemistry staining (Figure 1A, 1B). We also
observed different endogenous Tβ10 levels among 5 CCA
cell lines (Figure 1C, 1D). Three CCA cell lines (KKU-
M055, KKU-M156 and KKU-M213) had a relatively low
expression of Tβ10; while other two cell lines (KKU-M214
and KKU-100) had a relatively high expression of Tβ10.Figure 1 Endogenous expression of Tβ10 in CCA tissue specimens an
CCA surgical specimens were collected from the operating room under an
tumor and metastatic tumor of each CCA case were analyzed by using rea
metastatic site than that in the primary tumor tissue (*P<0.05; n=10). (B) Tβ
determined by immunohistochemistry. (C) Tβ10 mRNA levels were also ex
M214 and KKU-100) by real time RT-PCR. (D) Tβ10 protein levels were dete
KKU-M214 and KKU-100).These expression data provide a strong rationale for the
functional analysis of Tβ10 in CCA.
Silence of Tβ10 promotes cell migration and
monolayer wound healing in liver fluke-induced
cholangiocarcinoma cells
To study the potential function of Tβ10 in CCA, we de-
termined the effect of Tβ10 silence on cell migration in
a KKU-M214 cell line, which showed a high expression
of Tβ10. KKU-M214 cells were transfected with 50 pM
of Tβ10 siRNA (Ambion); and this reduced Tβ10 mRNA
levels by 50% at different time points (48, 72 and 96 h)
and Tβ10 protein levels dramatically by immunocyto-
chemistry analysis (Figure 2A). We performed migration
and invasion assays by using a modified Boyden cham-
ber method, and found that silence of Tβ10 significantly
enhanced cell migration and invasion of KKU-M214-
siTβ10 cells at 15 h and 18 h, compared with those of
KKU-M214-scramble RNA cells transfected with the
scramble RNA (Figure 2B, 2C; *P<0.05; n = 3).
To further confirm the role of Tβ10 silence in CCA
migration, we established stable cell lines with Tβ10 si-
lence in two CCA cell lines KKU-M214 and KKU-M055
by the retroviral vector delivery system and puromycin
selection. Silencing of Tβ10 in these cell lines was care-
fully confirmed by real time RT-PCR. The Tβ10 mRNAd cell lines. To investigate the expression of Tβ10 in CCA, 10 pairs of
approved research protocol. (A) Tβ10 mRNA levels of the primary
l time RT-PCR. Tβ10 mRNA levels were significantly lower in the
10 protein levels of a representative CCA case of paired tissues were
amined in 5 CCA cell lines (KKU-M055, KKU-M156, KKU-M213, KKU-
rmined by immunocytochemistry in three CCA cell lines (KKU-M213,
Figure 2 Effects of transient silence of Tβ10 on cell migration in KKU-M214 cell line. (A) KKU-M214 cells were treated with 50 pM Tβ10
siRNA or scramble siRNA as a control for 48, 72 and 96 h, respectively. Tβ10 mRNA and protein levels were determined by real time RT-PCR and
immunohistochemistry, respectively. (B) Migration and (C) invasion assays were carried out in KKU-M214 cells using a modified Boyden chamber
assay. Cells were pre-treated with Tβ10 siRNA or scramble siRNA for 48 h, and placed on Transwell to determine cell migration (15 h) and on
Transwell with pre-coated Matrigel (18 h) to determine cell invasion. Bar graphs represent fold change. n = 3, *P<0.05 versus the control.
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scramble vector control cells as well as a representative
of Tβ10 immunoreactivity are shown in Figure 3A. For
the cell migration assay, silence of Tβ10 in M214-sh-
Tβ10 cells was associated with 2.5 to 3-fold increase in cellFigure 3 Effects of stable silence of Tβ10 on cell migration and monolay
small hairpin Tβ10 RNA (sh-Tβ10) or control vector (sh-vector) were generated
confirmed by real time RT-PCR. β-actin was used as an internal control. Arrows
pictures show immunocytochemistry results of selected clones. (B) Stable Tβ1
incubation by the modified Boyden chamber assay. Bar graphs represent fold
carried out in M214-sh-vector and M214-sh-Tβ10 cells using DMEM medium s
same field at 0, 24, 30 and 36 h. (D) M214-sh-vector-GFP and M214-sh-Tβ10-G
of Tβ10 in stable silence cells (M214-sh-Tβ10-GFP cells and M214-sh-vector-GF
control. (F) Migration assay was carried out with M214-sh-vector-GFP and M21
assay. n = 3, *P<0.05 versus the control. (G)Wound healing assay for M214-sh
taken from the same field at 0, 20, and 24 h. (H) M214-sh-vector-GFP and M21
inhibitor III) for 2 h. Wound healing assay was performed. Representative imagmigration at 24 h and 48 h, respectively, compared with
that in M214-sh-vector cells (Figure 3B, *P<0.05; n = 3).
Similar results were also obtained in the monolayer wound
healing assay; and low expression of Tβ10 resulted in an
increase in cell migration of M214-sh-Tβ10 cellser wound healing in KKU-M214 cell line. Stable cell lines expressing
in KKU-M214. (A) All clones of control and Tβ10 silencing cells were
indicate selected clone for use in subsequent experiments; and insert
0 silence led to enhanced KKU-M214 cell migration in vitro in 24 and 48 h
change. n = 3; *P<0.05 versus the control. (C) Wound healing assay was
upplemented with 10% FBS. Representative images were taken from the
FP cells were established, showing GFP signals. (E) The expression levels
P cells) were determined by real time RT-PCR. n = 3, *P<0.05 versus the
4-sh-Tβ10-GFP cells at 48 h incubation by the modified Boyden chamber
-vector-GFP and M214-sh-Tβ10-GFP cells. Representative images were
4-sh-Tβ10-GFP cells were pre-treated with a Ras-GTPase inhibitor (FPT
es were taken from the same field at 0, 20, and 24 h.
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ence of 5 μg/mL Mitomycin C, which inhibits cell prolifer-
ation (Figure 3C).
In a parallel experiment, the M214-sh-vector and M214-
sh-Tβ10 cells were established by double transfection with
an eGFP expressing vector for use as a reporter signal for
the imaging purpose in the animal study. To ensure that
addition of eGFP did not alter Tβ10’s function in these
cells, we performed the migration and wound healing assay
in Tβ10 stable knockdown cells (M214-sh-Tβ10-GFP).
Cells infected with Lentivirus contained-eGFP plasmid
were selected in 1 μg/mL puromycin for 1 week before use
in experiments. Phase contrast images of cells were cap-
tured on an inverted fluorescent microscope using a 10×
objective to verify the green signal of GFP (Figure 3D).
After transducing eGFP into the cells, we confirmed the
expression of Tβ10 in M214-sh-vector-GFP and M214-sh-
Tβ10-GFP cells (Figure 3E). Then, we determined the
effects of Tβ10 silence once again. Indeed, Tβ10 silence
significantly increased the cell migration and monolayer
wound healing in M214-sh-Tβ10-GFP cells compared with
those in M214-sh-vector-GFP cells (Figure 3F, 3G). eGFP
did not affect the function of Tβ10 silence in vitro.
The functional role of Tβ10 silence was confirmed in
another CCA cell line KKU-M055, which has a relativelyFigure 4 Effects of stable silence of Tβ10 on cell migration and mono
expressing Tβ10 shRNA and control vector (sh-vector) were generated in K
were confirmed by real-time RT-PCR. β-actin was used as an internal contro
and insert pictures show immunocytochemistry results of selected clones.
modified Boyden chamber assay at 24 h incubation. Bar graphs represent f
M055 sh-vector and M055 sh-Tβ10 cells did not express eGFP gene. The gr
the migration assay. (C) Wound healing assay was determined in sh-Tβ10 a
field at 0, 24 and 40 h. (D) M055-sh-vector-GFP and M055-sh-Tβ10-GFP cell
Wound healing assay was performed. Representative images were taken frolow expression of Tβ10 (about 50% of Tβ10 in M214).
More CCA cell types studied in this project could dem-
onstrate that the effect of Tβ10 silence on CCA migra-
tion is not cell type specific. KKU-M055 was chosen for
both knockdown and overexpression of Tβ10. Stable silence
of Tβ10 was successfully established in M055 (Figure 4A);
silence of Tβ10 was associated with 3-fold increased cell
migration at 24 h in M055-sh-Tβ10 cells, compared with
those in sh-vector control cells (Figure 4B, *P<0.05; n = 3).
For the monolayer wound healing assay, one directional
migration was substantially increased in M055-sh-Tβ10
cells, compared with that in M055-sh-vector control
cells (Figure 4C). These results demonstrate that Tβ10
negatively regulates CCA cell migration in vitro, which
may play a critical role in the metastasis of CCA.
Forced overexpression of Tβ10 decreases cell migration
and monolayer wound healing in fluke-induced
cholangiocarcinoma cells
In order to further confirm the critical functions of Tβ10
in cell migration, we determined the effects of Tβ10 over-
expression in two CCA cell lines KKU-M055 and KKU-
M213, which have a relatively low endogenous level of
Tβ10. The stable cell lines were established by a lentiviral
vector delivery system including pReceiver-Tβ10-Lv105layer wound healing in KKU-M055 cell line. Stable cell lines
KU-M055 cell line. (A) All clones of control and Tβ10 silencing cells
l. Arrows indicate selected clone for use in subsequent experiments;
(B) Cell migration of sh-Tβ10 and sh-vector cells was studied by the
old change or percentage of control. n = 3; *P<0.05 versus the control.
een fluorescent signal in these cells was from Calcein-AM staining for
nd sh-vector cells. Representative images were taken from the same
s were pre-treated with a Ras-GTPase inhibitor (FPT inhibitor III) for 2 h.
m the same field at 0, 20, and 24 h.
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trol vector (GeneCopoeia). By real time RT-PCR analysis,
overexpression of Tβ10 in KKU-M055 (M055-Lenti-Tβ10)
or KKU-M213 (M213-Lenti-Tβ10) cell lines was confirmed,
compared with the M055-Lenti-GFP or M213-Lenti-GFP
control cells, respectively (Figure 5A, 5D). In Figure 5A,
we chose the M055 control cell clone (GFP C6), which
had a lowest expression of Tβ10, and the M055 stable
overexpression clone (Tβ10 C7), which had a highestFigure 5 Effects of stable overexpression of Tβ10 on cell migration an
M214 sh-Tβ10-GFP cells. Stable cell lines overexpressing Tβ10 (Lenti-Tβ10
and KKU-M213 cell lines. Selected clones of control and Tβ10 overexpressin
RT-PCR. β-actin was used as an internal control. Arrows indicate selected cl
M055 (B) and KKU-M213 (E) cells expressing Lenti-Tβ10 and its controls wa
incubation. Bar graphs represent fold change or percentage of control. n =
KKU-M055 (C) and KKU-M213 (F). Representative images were taken from t
KKU-M213 overexpression stable cell line. (G) Rescue experiment in KKU-M
with Tβ10 expressing plasmid for 48 h; while the sh-vector-GFP cells receiv
these cells were determined by real time RT-PCR. (H) Cell migration of M21
were determined by the modified Boyden chamber assay at 60 h incubatio
the control. (I) Wound healing assay was determined in M214 sh-Tβ10-GFP
images were taken from the same field at 0, 20, and 24 h.expression of Tβ10, for further study because these clones
may be more sensitive to determine the function of Tβ10
in CCA. Tβ10 mRNA levels in M055-Lenti-Tβ10 cells or
M213-Lenti-Tβ10 cells were increased by 2.7-fold or 2.5-
fold, respectively, compared with M055-Lenti-GFP cells or
M213-Lenti-GFP cells. For the cell migration assay, cell mi-
gration of M055-Lenti-Tβ10 cells or M213-Lenti-Tβ10 cells
was 80% or 87% lower than those of M055-Lenti-GFP cells
or M213-Lenti-GFP cells at 36 h, respectively (Figure 5B,d monolayer wound healing in KKU-M055, KKU-M213 and KKU-
) and GFP control plasmid (Lenti-GFP) were generated in KKU-M055
g KKU-M055 (A) and KKU-M213 (D) cells were confirmed by real time
one for use in subsequence experiments. Migration potential of KKU-
s determined by the modified Boyden chamber assay at 36 h
3; *P<0.05 versus the control. Wound healing assay was determined in
he same field at 0, 24, and 48 h in KKU-M055, and 0, 20, and 24 h in
214 sh-Tβ10-GFP cells. KKU-M214 sh-Tβ10-GFP cells were transfected
ed pCMV vector plasmid as a control. The expression levels of Tβ10 in
4 sh-Tβ10-GFP + Tβ10 plasmid cells and sh-vector-GFP + pCMV cells
n. Bar graphs represent percentage of control. n = 3; *P<0.05 versus
+ Tβ10 plasmid cells and sh-vector-GFP + pCMV cells. Representative
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assay, Tβ10 forced overexpression also resulted in a lower
cell migration rate in both M055-Lenti-Tβ10 and M213-
Lenti-Tβ10 cells, compared with that in their vector control
cells (Figure 5C, 5F). These data demonstrate the suppres-
sion role of Tβ10 in cell migration of CCA.
To determine the specificity of the functional role of
Tβ10 in CCA, we performed a rescue experiment in M214
sh-Tβ10-GFP cells, which have a reduced Tβ10 level and
increased cell migration. We hypothesized that reintrodu-
cing Tβ10 into this cell line would reverse its phenotype.
We transiently transfected a pCMV6-XL5-Tβ10 overex-
pression plasmid (OriGene) into the M214 sh-Tβ10-GFP
cells and found that their Tβ10 expression was 35-fold
greater than those of pCMV6-XL5 empty vector control
cells (Figure 5G). More importantly, forced Tβ10 overex-
pression completely reversed the promotion of cell mi-
gration caused by shRNA silencing of Tβ10 in both theFigure 6 Effects of stable silence of Tβ10 on tumor metastasis of KKU
sh-Tβ10-GFP cells were injected orthotopically into the spleen of nude mic
medial and left lobes (bottom) were excised and GFP expressing tumors (b
Graph showing the total number of GFP+ gross liver nodules in individual
Frozen sections of the liver were cut from the caudate and left lobe of eac
a 10× objective to verified the green signal of GFP; and 6 fields of GFP ind
(bottom). (D) The number of liver micrometastasis foci was quantified (±SD
M214 sh-Tβ10-GFP cell line-derived tumors compared with M214 sh-vectormodified Boyden chamber and the monolayer wound
healing assays (Figure 5H, 5I).
Stable silence of Tβ10 promotes tumor metastasis of
fluke-induced cholangiocarcinoma cells in nude mice
As shown in Figure 3D, we established M214 sh-Tβ10
and M214 sh-vector control cells with GFP expression,
which can be used for the imaging of tumor metastasis
in vivo. The effect of Tβ10 silence on the metastasis of
CCA was analyzed in vivo using an immunodeficient nude
mouse model. Twenty days after cells were injected or-
thotopically into the spleen of nude mice, the mice were
sacrificed, and liver metastases were examined. The num-
ber of tumor metastasis nodules of the liver in the group
of the mice injected with M214 sh-Tβ10-GFP cells was
greater than that in the mice injected with M214 sh-
vector-GFP control cells (Figure 6A, 6B). In addition, me-
tastasis nodules were observed in omental parenchyma in-M214 cell line in nude mice. (A) M214-sh-vector-GFP cells or M214-
e for 3 weeks. Spleen (top), right and caudate lobes of liver (middle),
lack arrows) were examined using an UV illuminating system. (B)
livers (±SD; n = 4). (C) Representative pictures of liver micrometastasis.
h mouse and visualized under a inverted fluorescent microscope using
icated area of each liver section were taken (top) and stained for H&E
; n = 4, *P<0.05 versus the control). (E) Tβ10 silence persisted in the
-GFP cell line-derived tumors by real-time RT-PCR.
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while 1 out of 4 mice injected with M214 sh-vector-GFP
control cells had metastasis in the omental parenchyma.
To observe liver micrometastasis, the liver tissues were
sectioned and imaged for fluorescent GFP signal (CCA tu-
mors), and the number of liver micrometastatic foci was
counted under the fluorescent microscope. Micrometa-
static lesions in the livers of mice injected with M214 sh-
Tβ10-GFP cells were significantly more than that of mice
injected with M214 sh-vector-GFP control cells (Figure 6C,
6D, *P<0.05, n = 4). We confirmed that Tβ10 silence per-
sisted in the nude mouse tumor derived from M214 sh-
Tβ10-GFP cells by real-time RT-PCR (Figure 6E). These
results demonstrate that stable silence of Tβ10 promotes
the liver metastasis of CCA cells in the nude mouse model.
Silence of Tβ10 activates signaling pathways involved
in tumor metastasis in fluke-induced
cholangiocarcinoma cells
It is well known that ERK1/2, EGR1 and the zinc-finger
transcription factor, Snail, play critical roles in tumor
metastasis in several cancer types [24-27]. However, it is
not clear whether these signaling pathways are involved
in the CCA. Cell lysates and nuclear extracts from KKU-
M055 and KKU-M214 cell lines with stable Tβ10 silence
or vector control cells were harvested and used for im-
munoblotting to detect the levels of total and phosphor-
ylated ERK1/2, EGR1 and Snail. β-actin and histone H1
were used for loading controls. Stable silence of Tβ10 in
both KKU-M055 and KKU-M214 substantially activated
ERK1/2 and increased Snail protein levels, but not EGR1
protein levels compared with that in vector control cells
(Figure 7A, 7B). The mRNA levels of Snail and EGR1
were substantially increased in these CCA cells with Tβ10
silence (Figure 7C, 7D). Thus, ERK1/2 and Snail pathways
may be involved in the functional role of Tβ10 silence-
induced metastasis in CCA.
Since activated Ras can stimulate ERK1/2 in many
cancer types [28], we hypothesized that the Ras-GTPase
inhibitor may block activation of ERK1/2 and expression
of EGR1 and Snail in Tβ10-silenced CCA cell lines. We
treated stable Tβ10 knockdown cells (M055-sh-Tβ10 and
M214-sh-Tβ10) and their vector control cells (M055-sh-
vector and M214-sh-vector) with a Ras-GTPase inhibitor,
FPT inhibitor III, (100 μM, Calbiochem, San Diego, CA)
and performed Western blot analysis for phosphorylation
of ERK1/2 and expression of EGR1 and Snail protein. FPT
inhibitor III significantly inhibited activation of ERK/1/2 in
both M055-sh-Tβ10 and M214-sh-Tβ10 cells (Figure 7A);
and FPT inhibitor III also inhibited upregulation of Snail in
both M055-sh-Tβ10 and M214-sh-Tβ10 cells (Figure 7B).
In addition, pretreatment of FPT inhibitor III (100 μM for
2 h) inhibited the wound healing in both M214-sh-Tβ10-
GPF cells (Figure 3H) and M055-sh-Tβ10 cells (Figure 4D).Matrix metalloproteinases (MMPs) also play a critical
role in cancer migration, invasion and metastasis [29]. We
determined the expression of MMP3, MMP7 and MMP9
in stable Tβ10 knockdown cells (M055-sh-Tβ10 and M214-
sh-Tβ10) and their vector control cells (M055-sh-vector
and M214-sh-vector) by real time RT-PCR analysis. M055-
sh-Tβ10 cells had a higher mRNA level of MMP3, MMP7
and MMP9 than the vector control cells had (Figure 7E).
Similarly, M214-sh-Tβ10 cells had a higher expression
of MMP3 and MMP9 than M214-sh-vector cells had
(Figure 7F). Thus, the loss of Tβ10 in CCA may increase
the expression of MMPs, which contribute to the en-
hanced migration and invasion of CCA cells.
Discussions
In the current study, the functional role of Tβ10 in cell
migration and tumor metastasis of CCA cell lines were
investigated. Suppression of Tβ10 expression in CCA
cell lines using siRNA-Tβ10 or shRNA-Tβ10 increases
cell migration in vitro and enhances tumor metastasis in
the nude mouse model. These results strongly suggest
that suppression of Tβ10 in the primary CCA may in-
crease its aggressiveness, possibly triggering some key
signaling pathways for tumor metastasis.
There are numerous studies suggesting the critical roles
for Tβ10 in tumorigenesis and progression of human can-
cers [20,23,30-34]. Expression of Tβ10 has been shown to
confer cell migratory advantage in thyroid carcinoma
[17,18,35,36], and melanoma [19,31,37]; but disadvantage
in endothelial cells [38] and ovarian cancer [24]. However,
roles of Tβ10 in cancer development such as cell growth
and apoptosis still remain controversial among cancers
[15,16]. At present, little is known about the expression
and functions of Tβ10 in CCA. Using expressed sequence
tags, Tβ10 was reported to be upregulated in intrahepatic
CCA compared with normal liver tissues [39]. In this
study, however, using real-time RT-PCR, we provide evi-
dence, for the first time, that Tβ10 is upregulated in pri-
mary CCA; while it is significantly decreased in the
metastatic CCA tumors. Functionally, reducing Tβ10 ex-
pression by transiently and stably silencing technologies
significantly enhanced the migration of CCA cell lines.
Recently, there have been many reports that describe
the potential functional roles of Tβ10 in human cancers;
however, these functions are quite different among dif-
ferent types of cancers. Tβ10 induces antiproliferative
and proapoptotic effects in ovarian cancer; while in pan-
creatic cancer, Tβ10 stimulates secretion of proinflam-
matory cytokines interleukin (IL-7) and IL-8, which may
promote pancreatic cancer pathogenesis and progression
[23]. Tβ10 inhibits tumor growth, angiogenesis, migration,
and invasion of ovarian cancer in vitro and in vivo studies
by disrupting actin polymerization and by inhibiting Ras
action [24]. In our study, we demonstrate that Tβ10
Figure 7 Effects of Tβ10 silence on ERK1/2 phosphorylation and the expression of EGR1, Snail and MMPs in KKU-M055 and KKU-M214
cell lines. (A) M055 sh-Tβ10 cells and M214 sh-Tβ10 cells as well as their vector control cells were grown in the complete medium for 24 h.
Phosphorylated form and total form of ERK1/2 were determined by Western blot analysis. β-actin was used as a loading control. Intensity of the
immunoreactive bands was measured by ImageJ software. This assay was repeated with pretreatment of a Ras-GTPase inhibitor (FPT inhibitor III,
100 μM, 2 h). (B) EGR1 and Snail protein levels in M055 sh-Tβ10 cells and M214 sh-Tβ10 cells as well as their vector control cells were determined
by Western blot. Histone H1 was also included as a loading control. Intensity of the immunoreactive bands was measured by ImageJ software.
This assay was repeated with pretreatment of a Ras-GTPase inhibitor (FPT inhibitor III, 100 μM, 2 h). The mRNA levels of Tβ10, EGR1 and Snail in
M055 sh-Tβ10 cells (C) and M214 sh-Tβ10 cells (D) as well as their vector control cells were determined by real time RT-PCR analysis. Also, the
mRNA levels of MMP3, MMP7 and MMP9 in M055 sh-Tβ10 cells (E) and M214 sh-Tβ10 cells (F) as well as their vector control cells were
determined by real time RT-PCR analysis. All data were normalized to β-actin mRNA levels in these cells.
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lines (KKU-M055 and KKU-M214 cells); while forced over-
expression of Tβ10 in CCA cell lines (KKU-M055, KKU-
M213) has an inhibitory effect on CCA migration. The
function of Tβ10 is specific because the effect of Tβ10 si-
lence can be reversed by overexpression of Tβ10 in CCA
cell lines. Tβ10 transiently silenced by siRNA oligonucleo-
die in KKU-M214 cells significantly increased both migra-
tion and invasion in M214 cells in vitro. However, the
invasion was increased more than the migration in M214
cells with Tβ10 silence. The reason for the difference of in-
vasion and migration in the same cell type is not clear. It is
possible that the migration and invasion have different mo-
lecular mechanisms. Invasion requires local proteolysis of
the extracellular matrix (ECM), pseudopodial extension,
and cell migration [40,41].
From technical aspects, sh-RNA retrovirus construct
for Tβ10 (sh-Tβ10) and empty control vector (sh2003)
were used to infect both M214 and M055 CCA cells to
establish stable silence cell lines by puromycin selection.
Control vector nonspecifically reduced Tβ10 mRNA in
M214 clones, but did not affect Tβ10 levels in M055. It
is possible that different types of cells may contribute to
this discrepancy. M214 was derived from a moderately
differentiated CCA; while M055 was derived from a poorly
differentiated CCA [21,22]. For the wound healing assay,
control cells M055 Lenti-GFP had a lower wound healing
rate compared with the control cells M213 Lenti-GFPalthough both cell types had a similar expression level of
Tβ10. It is possible that different types of CCA cell lines
have different mechanisms to control cell migration. Under
the culture condition, M055 cells grow slower than M213
cells. In the rescue experiment, Tβ10-overexpressing plas-
mid was transiently transfected into the Tβ10 stable knock-
down cells (M214 sh-Tβ10-GFP) and caused a 35-fold
increase of Tβ10 mRNA levels compared with that in vec-
tor control cells. It is possible that the overexpression of
Tβ10 from the transiently transfected plasmid was strong
and overcome sh-Tβ10-mediated degradation of Tβ10 in
these rescue cells.
More importantly, we also demonstrate that silence of
Tβ10 in CCA cell lines enhanced tumor metastasis in
the nude mouse model. These data may indicate clinical
significance of the suppression of Tβ10 in metastatic
CCA. Our results were consistent with previous studies
in endothelial cells [38] and ovarian cancer [24,42,43].
However, it is not clear why metastatic CCA has a re-
duced expression of Tβ10. A current study has reported
that approximately 16.7% of CCA have KRAS mutations
[44], resulting in constitutively active Ras, which may
contribute to the loss of Tβ10 expression. Other studies
report that Tβ10 is differentially regulated by many fac-
tors such as retinoic acid and retinoids, growth factors
and steroid hormones. For examples, vascular endothe-
lial growth factor (VEGF), thyroid-stimulating hormones
(TSH) upregulate Tβ10 expression in a dose-dependent
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as 5-Fluorouracil (5-FU) has been shown to affect Tβ10
expression [45]. Thus, Tβ10 could be an important bio-
marker for 5-FU treatment.
Cell migration is a complex biological process involving
highly orchestrated multistep process network of proteins
and regulatory pathways. One of these regulatory pathways
is the ERK1/2 MAPK pathway, which transduces extracel-
lular signals into intracellular responses and is necessary
for many cellular events [46,47]. To address regulatory
pathways, which are associated with the functional role of
Tβ10 silence in CCA, we determined the correlation be-
tween Tβ10 silence and activation of ERK1/2. Indeed,
when Tβ10 was silenced in CCA cell lines, phosphoryl-
ation of ERK1/2 was substantially increased. It has been
reported that ERK-mediated phosphorylation of FAK at
Ser910 inhibits the interaction of FAK with paxillin, then
regulate of the FAK-paxillin complex and it is possible that
ERK-modulated disassembly of the FAK-paxillin complex
is involved in focal adhesion disassembly [48]. This em-
phasizes that ERK is an important factor in the regulation
of cell migration.
It is unknown how silence of Tβ10 increases cell migra-
tion and metastasis of CCA. However, it is possible that
suppression of Tβ10 increases the free form of G-actin,
which is available for the dynamic actin polymerization es-
pecially in the cell front, thus enhances cell migration and
tumor metastasis. Furthermore, Tβ10 is a key factor that
interacts with Ras and inhibits Ras-dependent ERK1/2 sig-
naling pathway [24]. It is recently reported that ERK1/2
activation mediates the expression of EGR1, which subse-
quently increases the invasive capability of ovarian cancer
cells [49]. EGR1 also activates expression of Snail [50], a
key inducer of epithelial-mesenchymal transition (EMT),
which plays an important role in cancer metastasis [51-54].
In our current study, we demonstrate that Tβ10 silence-
induced cell migration and metastasis of CCA may also in-
volve ERK12, EGR1 and Snail pathways. Silence of Tβ10
substantially activated ERK1/2, and increased mRNA and
protein levels of Snail and mRNA levels of EGR1 in CCA
cell lines. However, silence of Tβ10 did not increase pro-
tein levels of EGR1. It is possible that Snail binds to the
EGR1 promoter and represses EGR1 transcription, as well
as its own promoter, thereby establishing a negative regula-
tory feedback loop [50,55,56].
In addition, activation of ERK1/2 can be caused by
KRAS mutation in many cancer types [28]. Our data
also confirm this possibility in CCA. The Ras-GTPase
inhibitor, FPT inhibitor III, effectively blocked the activation
of ERK1/2 and the expression of Snail as well as the wound
healing rate in Tβ10-silenced CCA cell lines (M055-sh-
Tβ10 and M214-sh-Tβ10).
Furthermore, high expression levels and activities of
MMPs contribute to the invasiveness and metastasispotential in many types of cancers [29]. In the current
study, we determined the relationship between silence of
Tβ10 and expression of MMPs in CCA cell lines. Our data
showed that stable Tβ10 knockdown cells (M055-sh-Tβ10
and M214-sh-Tβ10) had a relatively higher expression of
MMP3, MMP7 and MMP9 than their control cells. The
loss of Tβ10 in CCA may have a causal relationship with
the increased expression of MMPs, which may enhance
CCA metastasis.
Currently, functional roles and regulation mechanisms
of Ras, ERK1/2, EGR1, Snail and MMPs in CCA metas-
tasis are not fully understood. Further investigation into
the whole picture of signaling mechanisms and protein
interactions mediated by Tβ10 is warranted. It is not
clear whether the current findings obtained from the re-
search in the fluke-associated CCA are applicable to
other types of CCA with different etiology. Now, there
are no reports on the relationship between Tβ10 and
other types of CCA. It could be a great opportunity for
future investigation.
Conclusions
The present study demonstrates that Tβ10 expression is
relatively high in the primary CCA tumor tissues; while it
is dramatically reduced in the metastatic tumors. Over-
expression of Tβ10 reduces cell migration; whereas silence
of Tβ10 expression enhances CCA cell migration and in-
vasion in vitro. Loss of Tβ10 expression accelerates tumor
metastasis of CCA in the nude mouse model. Silence of
Tβ10 mediates migration of CCA cells possibly through
the activation of Ras, ERK1/2 and upregulation of Snail
and MMPs. More studies in the molecular mechanisms of
Tβ10 associated with cell migration and metastasis in
CCA are warranted in order to develop new strategies to
treat CCA.
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